Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?
J Thorac Dis
; 10(2): 740-748, 2018 Feb.
Article
em En
| MEDLINE
| ID: mdl-29607144
ABSTRACT
BACKGROUND:
Osteopontin (OPN) is involved in cancer development and metastasis. Increased sputum OPN was detected in chronic obstructive pulmonary disease (COPD).METHODS:
We evaluated serum OPN levels in patients with lung cancer (LC) and/or COPD and aimed to determine OPN prognostic performance in 1-year mortality in LC and also its diagnostic performance in LC among COPD patients. We recruited 167 LC patients, 85 with concomitant COPD. 28 COPD patients served as control group.RESULTS:
OPN levels were higher in LC compared to COPD alone (P=0.017) and higher in COPD and LC compared to COPD alone (P=0.031). No difference was observed in OPN levels between LC and COPD vs. LC without COPD (P=0.171). Serum OPN ≥50.3 ng/mL was an independent predictor of 1-year mortality in LC.CONCLUSIONS:
OPN levels ≥35 ng/mL could predict the presence of LC among COPD patients. In patients with LC and/or COPD, LC is the major determinant for serum OPN. Serum OPN might be a promising prognostic biomarker of LC and a diagnostic biomarker of LC among COPD patients.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
J Thorac Dis
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Grécia